Scancell confirms advanced talks over reverse merger with Neuphoria

Impact · against what's priced in

Scancell's potential Nasdaq listing and Phase III funding efforts are material catalysts that could improve liquidity and clinical progression. EnergyPathways' move to the FEED stage and the confirmation of project viability by Siemens Energy represent concrete technical progress for its energy storage project.

EPP+0.80: No priced-in read yet
In context: Launching Front End Engineering and Design (FEED) following viability confirmation from Siemens Energy and securing £15 million in financing significantly reduces the technical risk of the compressed air energy storage project.
Read from the article alone

Scancell confirms advanced talks over reverse merger with Neuphoria

biotech
m and a
ENR
EPP
SCLP
cancer therapy
clinical trials
energy storage
financing
nasdaq
pharma

Scancell confirms advanced talks over reverse merger with Neuphoria

What matters in this story

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

Scancell confirms advanced talks over reverse merger with Neuphoria

What matters in this story

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

How each ticker is affected

Connected tickers

Track these names every morning.

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

What Energy Vault (NRGV) Said on Its Q3 Earnings Call

Scancell confirms advanced talks over reverse merger with Neuphoria

What matters in this story

Next reads from the same story arc

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

Scancell confirms advanced talks over reverse merger with Neuphoria

What matters in this story

Next reads from the same story arc

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

How each ticker is affected

Connected tickers

Track these names every morning.

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

What Energy Vault (NRGV) Said on Its Q3 Earnings Call